echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Adimab announced that it will cooperate with GlaxoSmithKline to develop bispecific antibodies

    Adimab announced that it will cooperate with GlaxoSmithKline to develop bispecific antibodies

    • Last Update: 2015-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley 2015-01-15 with the deepening of medical research, people are more and more aware of the important role of drug targeting in disease treatment Therefore, antibody drugs with good targeting have also received unprecedented attention from drug developers It has become a consensus of many people that antibodies can recognize antigens specifically and singly However, for some diseases such as tumors, single specific antibodies may not be able to complete this task well In view of this, adimab, a famous biotechnology company, has focused its research on finding bispecific antibodies and established a unique platform The researchers first isolated two different monoclonal antibodies, purified them and then coupled them in a certain way, so as to synthesize a bispecific antibody with different targeting properties This technology has a broad prospect in the treatment of some complex diseases Recently, adimab announced an agreement with pharmaceutical giant GlaxoSmithKline to jointly develop bispecific antibodies According to the agreement, adimab will use the company's unique antibody technology to establish an antibody library for GlaxoSmithKline to screen multi-target antibodies GlaxoSmithKline became the first company to reach a similar service agreement with adimab Neil brewis, who is responsible for the research and development of GSK biomedicine, also expressed his expectation for this Agreement: adimab's bispecific antibody technology can quickly screen stable bispecific antibodies for GSK, which will help GSK to better screen appropriate drug molecules in this field in the future Adimab company is not infamous either The human full-length antibody development and search technology platform developed by the company can synthesize and purify human full-length antibody at an unprecedented speed At present, the company's main business scope is to provide corresponding antibody screening services for various biomedical companies Its partners include more than 20 biomedical companies including MSD, Roche and Lilly  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.